{"analyses":[{"ciLowerLimit":"5.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"26.92","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0016","paramType":"Difference in Overall Response Rates","paramValue":"16.30","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"58.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"185"}],"units":"Participants"}],"description":"An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1.","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"NUMBER","populationDescription":"The PD-L1-ORR-evaluable population is defined as patients in the PD-L1-selected subpopulation with measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 34 months","title":"Percentage of Participants With an Objective Response of CR or PR According to RECIST v1.1 in Participants With Detectable PD-L1","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}